Life After a Tricuspid Valve Trial: What the Data Didn't Show
- maryrburrell
- 18 minutes ago
- 4 min read
Five years ago, traditional surgery was completely off the table for torrential tricuspid regurgitation. Running out of options, I made a last-ditch effort and joined a groundbreaking transcatheter trial as an early pioneer. I left with a 52mm bioprosthetic valve beating inside my chest.
Now that I've officially crossed the finish line of this five-year trial, I can look back with perspective. From a data standpoint, my participation was a flawless corporate and clinical triumph. My heart gradients are stable, my severe shortness of breath is gone, and I'm in the gym lifting weights, tackling ellipticals and treadmills.
The data said success. This is what it took to get here
To the trial designers, sponsors, and principal investigators reading this: your engineering is life-changing. But if we want to truly revolutionize structural heart innovation, we have to look past the data points and look at what it actually takes for a human being to survive the protocol.
Here's what I got, what was missing, and how we have to change the future of clinical trial design.
What the Data Captures vs. What the Patient Endures
Clinical trials are meticulously designed to track the device. They often fail to wrap around the patient during the most volatile chapters of our recovery.
What I Got: Groundbreaking Engineering
A pioneering second chance. The device successfully restructured my cardiac function, replacing an overwhelming, torrential leak with trace-to-no residual regurgitation.
Rigorous surveillance. For half a decade, a brilliant medical team watched my labs, my echos, and my clinical endpoints with absolute precision.
A return to functional life. I went from an impossible baseline to someone maintaining an active, independent life.
What Was Missing: The Acute Human Gaps
The terrifying medical tightrope. The first 30 days after my deployment were a terrifying medical tightrope. I faced a sudden tricuspid valve thrombosis, dangerous potassium drops, and wild weight and fluid spikes. The engineering was a success but the daily survival of these fast-moving, post-op complications felt like an unmapped wilderness for me and my family.
Rehab timing that didn't match my healing. Trial protocols love a standardized timeline, but human healing doesn't follow a rigid calendar. I completed cardiac rehab, but my lived experience exposed a real flaw in the trial's design: I was pushed into it too soon, before my body was actually ready. Because my system was still reeling from the procedure, I spent those early sessions battling severe blood pressure drops, shortness of breath, profound weakness, and dizziness, instead of actually building strength. I would have gotten far greater benefit, and protected my limited energy, if rehab had started based on where my body actually was once my dry weight, fluid status, and blood pressure had fully stabilized instead of forcing me to check a box before my heart was ready.
The high-stakes handoff. My local cardiologist was ready to pick up right where the trial team left off, but the actual transition was a blurry mess. In the beginning, I was completely confused about who to update, and with what. I was told to reach out to my local doctor, but I hadn't realized that during the trial, it was actually the trial doctors managing my day-to-day heart care. That "in-between" space was an administrative blind spot leaving me to guess who was steering the ship whenever my symptoms flared, instead of having a clear, standardized protocol to follow.
The Ripple Effect: Your Data, Their Future
To every patient wondering if a clinical trial is worth the terrifying risk: know that your lived experience is the ultimate blueprint. When you stand on the front lines and stay the course, you are not only a data repository you're handing researchers the exact real-world proof they need to make the next patient's recovery safer, and to prove these heart devices actually last.
Because I stayed the course, my five years of data helped open the door for broader regulatory approval. It helped transform a procedure that was once a scary, last-chance experiment into a mainstream, accessible reality that will save thousands of lives globally. We didn't just test a piece of medical engineering we proved a future exists for patients who were once told they'd completely run out of options.
A Call to Action for Clinical Trial Designers
True innovation can't stop the moment a device is successfully deployed. If the medical industry wants authentic, patient-centered breakthroughs, clinical trials have to evolve and not just the devices they test.
Budget for navigation and data. I challenge trial sponsors to build post-op navigation support directly into study budgets, to help patients manage the unpredictable fluid and medication shifts in early recovery.
Flex the rehab timeline based on readiness, not time. Stop treating rehab like a rigid, calendar-based checkbox. I challenge trial designers to build protocols that evaluate individual patient readiness based on real signs of stability blood pressure, fluid balance, baseline strength not only elapsed weeks. Forcing an unready body into exertion is a safety hazard, not a recovery plan.
Standardize the care handoff. Create and fund structured shared-care communication channels, so local, general cardiologists are fully equipped to manage trial patients without risking heart failure readmissions.
Don't just track us for five years and walk away. This is where #HeartBridgeCollective comes in partner with us, and use our lived experience to build a compassionate, sustainable roadmap for the thousands of patients walking behind us.
The device is ready. The next innovation isn't a valve, it's how we care for the people who live with one.